Entecavir

Routes
Oral (PO)
Half-Life (t½)
PO: 5.4d
Formula
C12H15N5O3
Molecular Weight
277.28 g/mol
PubChem CID
135398508
Aliases
Baraclude

Pharmacological Mechanism

Guanosine nucleoside analog — selective HBV polymerase inhibitor. First-line oral therapy for chronic HBV with high barrier to resistance + minimal HIV cross-activity. Renal excretion; food reduces F.

Half-Life & Elimination Curve (PO: 5.4d)

100%50%25%12.5%0%0h0×t½5.4d1×t½10.8d2×t½16.3d3×t½21.7d4×t½27.1d5×t½0×t½ (0h): 100% remaining (~10.9 µg/L)1×t½ (5.4d): 50% remaining (~5.45 µg/L)2×t½ (10.8d): 25% remaining (~2.72 µg/L)3×t½ (16.3d): 12.5% remaining (~1.36 µg/L)4×t½ (21.7d): 6.3% remaining (~0.681 µg/L)5×t½ (27.1d): 3.1% remaining (~0.34 µg/L)
Plasma (PO)t½ Decay (5.4d)
  • 0×t½0h100% (10.9 µg/L)
  • 1×t½5.4d50% (5.45 µg/L)
  • 2×t½10.8d25% (2.72 µg/L)
  • 3×t½16.3d12.5% (1.36 µg/L)
  • 4×t½21.7d6.3% (0.681 µg/L)
  • 5×t½27.1d3.1% (0.34 µg/L)
Elimination t½5.4d (PO)
Rate Constant (ke)0.00533 h⁻¹
Time to Peak (Tmax)7.02h
Est. Peak (Cmax)10.9 µg/L
Clearance (CL)0.224 L/h
97% Washout (5×t½)27.1d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References